EUCTR2004-001989-41-BE进行中（未招募）1 期
An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjects with previously untreated Multiple Myeloma. - Velcade-MMY-3002
J&J PRD, a division of Janssen-Cilag NV0 个研究点目标入组 680 人开始时间: 2005年7月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 680
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female
- •Subject is not a candidate for HDT/SCT due to:
- •age - subject is 65 years or older.
- •OR in subjects less than 65 years of age - presence of important comorbid condition(s) likely to have a negative impact on tolerability of HDT/SCT. Sponsor review of these comorbid conditions and approval is required before randomization.
- •Symptomatic multiple myeloma or asymptomatic multiple myeloma with related organ or tissue damage. Asymptomatic multiple myeloma-related organ or tissue damage can include presence of asymptomatic lytic bone lesion or plasmacytoma, or presence of anemia (hemoglobin <10 g/dL), renal function impairment (serum creatinine > upper limit of normal [ULN]) or hypercalcemia (serum calcium >ULN), as long as the criteria for pre-treatment clinical laboratory values indicated below are met.
- •Presence of measurable disease, defined as:
- •For secretory multiple myeloma, measurable disease is defined as any quantifiable serum monoclonal protein value (>1 g/dL of IgG or IgM M-protein, >0.5 g/dL of IgA M-protein, >0.05 g/dL of IgD M protein, OR urine light-chain excretion of more than 200 mg/24 hours).
- •For oligosecretory or nonsecretory multiple myeloma, measurable disease is defined by the presence of measurable soft tissue or organ (not bone) plasmacytomas as determined by clinical examination or applicable radiographs (i.e., magnetic resonance imaging [MRI], computed tomography [CT] scan). A measurable lesion is defined as a lesion with minimum largest diameter of >20 mm (if measured by conventional techniques such as physical examination, conventional CT scan, or MRI) or of >10 mm (if measured by spiral CT scan) in one dimension. Oligosecretory myeloma is defined as the presence of M-protein in serum or urine but in quantities less than indicated above. Nonsecretory multiple myeloma is defined as the absence of M protein in serum and in urine by immunofixation.
- •Karnofsky performance status score >60%
- •Have pretreatment clinical laboratory values meeting the following criteria within 14 days before randomization:
- •-platelet count greater or equal to 100x10*9/L
- •-hemoglobin greater or equal than 8 g/dL (greater or equal than 4.96 mmol/L) (prior RBC transfusion or recombinant human erythropoietin use is allowed)
- •-absolute neutrophil count (ANC) greater or equal than 1.0x109/L
- •-aspartate aminotransferase (AST) smaller or equal than 2.5 times the upper limit of normal
- •-total bilirubin lower or equal than 1.5 times the upper limit of normal
- •-serum creatinine smaller or equal to 2mg/dL (smaller or equal to176.8 mcmol/L)
- •-corrected serum calcium <14 mg/dL (<3.5 mmol/L)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Diagnosis of smoldering multiple myeloma or MGUS. Smoldering multiple myeloma is defined as asymptomatic multiple myeloma with absence of lytic bone lesions. MGUS is defined by presence of serum monoclonal protein <3 g/dL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the monoclonal protein; and (if determined) proportion of plasma cells in the bone marrow of 10% or less.
- •Diagnosis of Waldenstrom's disease or other conditions in which IgM M protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
- •Prior or current systemic therapy for multiple myeloma including steroids (with exception of emergency use of a short course [maximum 4 days] of steroids before randomization or of prior or current use of bisphosphonates)
- •Radiation therapy within 30 days before randomization
- •Plasmapheresis within 30 days before randomization
- •Major surgery within 30 days before randomization (Kyphoplasty is not considered major surgery)
- •History of allergic reaction attributable to compounds containing boron or mannitol
- •Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0
- •Uncontrolled or severe cardiovascular disease, including myocardial infarction, within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure (see Attachment 3), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
- •Other malignancy within the past 5 years. Exceptions for the following if treated and not active: basal cell or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ or International Federation of Gynecology and Obstetrics (FIGO) Stage 1 carcinoma of the cervix
- •Concurrent medical condition or disease (e.g., active systemic infection, uncontrolled diabetes) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study
- •Use of any investigational drugs within 30 days before randomization
研究者
相似试验
进行中（未招募）
不适用
An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjects with previously untreated Multiple Myeloma. - Velcade-MMY-3002EUCTR2004-001989-41-FIJanssen-Cilag Oy680
进行中（未招募）
1 期
An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjects with previously untreated Multiple Myeloma. - Velcade-MMY-3002First-Line Multiple MyelomaEUCTR2004-001989-41-ESJanssen-Cilag S.A.
进行中（未招募）
不适用
An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjects with previously untreated Multiple Myeloma. - Velcade-MMY-3002First-Line Multiple MyelomaEUCTR2004-001989-41-DEJanssen-Cilag Intrenational N.V.680
进行中（未招募）
不适用
An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjects with previously untreated Multiple Myeloma. - Velcade-MMY-3002EUCTR2004-001989-41-IEJanssen Cilag Limited680
进行中（未招募）
不适用
An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple MyelomaEUCTR2004-001989-41-ITJANSSEN-CILAG680